Vontobel Holding Ltd. Purchases 20,000 Shares of Adicet Bio, Inc. $ACET

Vontobel Holding Ltd. increased its position in Adicet Bio, Inc. (NASDAQ:ACET) by 33.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 80,000 shares of the company’s stock after purchasing an additional 20,000 shares during the period. Vontobel Holding Ltd. owned approximately 0.10% of Adicet Bio worth $49,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Wealthedge Investment Advisors LLC lifted its holdings in shares of Adicet Bio by 208.8% in the 1st quarter. Wealthedge Investment Advisors LLC now owns 227,801 shares of the company’s stock worth $172,000 after purchasing an additional 154,037 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Adicet Bio by 1.8% in the 1st quarter. Acadian Asset Management LLC now owns 2,039,324 shares of the company’s stock worth $1,538,000 after purchasing an additional 36,277 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Adicet Bio by 1.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock worth $2,882,000 after purchasing an additional 63,691 shares in the last quarter. 83.89% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. HC Wainwright upgraded Adicet Bio to a “strong-buy” rating and set a $4.00 target price on the stock in a report on Wednesday, July 23rd. Guggenheim increased their price target on Adicet Bio from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Adicet Bio in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group raised Adicet Bio to a “strong-buy” rating in a research report on Tuesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Adicet Bio currently has a consensus rating of “Moderate Buy” and an average target price of $5.67.

Adicet Bio Price Performance

Shares of Adicet Bio stock opened at $0.99 on Thursday. Adicet Bio, Inc. has a 1 year low of $0.45 and a 1 year high of $1.54. The firm has a market cap of $82.08 million, a PE ratio of -0.75 and a beta of 1.62. The stock has a fifty day moving average price of $0.78 and a 200-day moving average price of $0.71.

Adicet Bio (NASDAQ:ACET) last announced its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.02). As a group, equities analysts anticipate that Adicet Bio, Inc. will post -1.39 EPS for the current fiscal year.

Adicet Bio Company Profile

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.